Flubendazole elicits anti‐metastatic effects in triple‐negative breast cancer via STAT3 inhibition
暂无分享,去创建一个
Ji Young Kim | J. Seo | Lee Farrand | Y. Kim | Eunhye Oh | Hyunsook An | Tae-Min Cho | Daeil Sung | Seojin Jang
[1] Ji Young Kim,et al. Inhibition of ubiquitin-specific protease 34 (USP34) induces epithelial-mesenchymal transition and promotes stemness in mammary epithelial cells. , 2017, Cellular signalling.
[2] Ji Young Kim,et al. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells. , 2017, Biochemical and biophysical research communications.
[3] E. Rudolf,et al. Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy. , 2017, Acta medica.
[4] Ji Young Kim,et al. Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. , 2017, Cancer letters.
[5] Jiayuh Lin,et al. STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells , 2016, International journal of oncology.
[6] M. Zhong,et al. ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway , 2016, OncoTargets and therapy.
[7] Ji Young Kim,et al. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer. , 2016, Cancer letters.
[8] C. Ban,et al. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. , 2016, Biochimica et biophysica acta.
[9] H. Resat,et al. Constitutive activation of STAT3 in breast cancer cells: A review , 2016, International journal of cancer.
[10] E. Rudolf,et al. Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro , 2016, The Journal of pharmacy and pharmacology.
[11] Sriganesh Srihari,et al. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. , 2015, Trends in pharmacological sciences.
[12] Ji Young Kim,et al. Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells , 2015, PloS one.
[13] Manisha Singh,et al. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer , 2015, Scientific Reports.
[14] J. McCaffrey,et al. The fate of chemoresistance in triple negative breast cancer (TNBC) , 2015, BBA clinical.
[15] Hua Yu,et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.
[16] M. Quinn,et al. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden , 2014, BMC Cancer.
[17] Michael K. Wendt,et al. STAT3 and epithelial–mesenchymal transitions in carcinomas , 2014, JAK-STAT.
[18] M. Wicha,et al. Evaluation of STAT3 Signaling in ALDH+ and ALDH+/CD44+/CD24− Subpopulations of Breast Cancer Cells , 2013, PloS one.
[19] R. Gude,et al. Role of STAT3 in Cancer Metastasis and Translational Advances , 2013, BioMed research international.
[20] Ming Li,et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.
[21] E. Tokunaga,et al. Vimentin as a poor prognostic factor for triple-negative breast cancer , 2013, Journal of Cancer Research and Clinical Oncology.
[22] Mithat Gönen,et al. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.
[23] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[24] Georg Krupitza,et al. Initial steps of metastasis: Cell invasion and endothelial transmigration , 2011, Mutation research.
[25] André F. Vieira,et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype , 2011, Journal of Clinical Pathology.
[26] S. Lakhani,et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. , 2011, Carcinogenesis.
[27] T. Geary,et al. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs , 2011, Expert review of anti-infective therapy.
[28] S. Isakoff,et al. Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents , 2010, Cancer journal.
[29] C. Lanusse,et al. Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. , 2009, Parasitology international.
[30] M. Sukhai,et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. , 2009, Blood.
[31] Justin C. Grindley,et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.
[32] Eric S. Lander,et al. Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.
[33] Ps Patel,et al. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. , 2009, Indian journal of cancer.
[34] Carlos Caldas,et al. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.
[35] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[36] J. Weidhaas,et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Puisieux,et al. Metastasis: a question of life or death , 2006, Nature Reviews Cancer.
[38] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[39] F. Ali-Osman,et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis , 2004, Oncogene.
[40] M. Jordan,et al. Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.
[41] G. Dontu,et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.
[42] J. Abbruzzese,et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.
[43] P. Hahnfeldt,et al. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.
[44] L. Dufour,et al. Treatment of neurocysticercosis with flubendazole. , 1984, The American journal of tropical medicine and hygiene.
[45] D. Vuitton,et al. [Treatment of human alveolar echinococcosis with flubendazole. Clinical, morphological and immunological study]. , 1984, Gastroenterologie clinique et biologique.
[46] Ji Young Kim,et al. Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer. , 2018, Cancer letters.
[47] C. Hudis,et al. Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.
[48] W. Janzen,et al. High Throughput Screening , 2009, Methods in Molecular Biology.